Abstract. In antibody-directed enzyme-prodrug therapy (ADEPT), an antibody-bound enzyme localizes to tumor tissue, where it selectively converts a subsequently administered non-toxic prodrug into a cytotoxic drug. A33scFv::CDy is a bifunctional fusion construct comprising a single chain antibody against the gpA33 antigen and the prodrug-converting enzyme cytosine deaminase. gpA33 is highly and homogeneously expressed in >95% of all colorectal cancers. Here we describe the biodistribution and tumor- :CDy peaked at 87% injected dose/g 47 h post injection. Normal tissue uptake was low, and activity in blood was lower than in tumor at all time-points studied (6-92 h). The tumor-to-blood ratio increased over time with a maximum of 8.1 at 67 h post injection. [ 131 I]A33scFv::CDy thus shows a biodistribution that makes it attractive for both radioimmunotherapy (RIT) and ADEPT. Preliminary therapeutic experiments showed a significant reduction of tumor size in mice treated with the A33scFv::CDy-5-fluorocytosine/5-fluorouracil ADEPT system. This work demonstrates the feasibility of ADEPT and RIT based on the A33scFv::CDy recombinant construct.
Introduction
Monoclonal antibodies (mAb) have become an accepted modality of cancer therapy. Recombinant antibodies and antibody-based fusion proteins hold the promise of further extending therapeutic possibilities. Single chain variable fragments (scFv) consist of the variable regions of an antibody's heavy and light chains fused together via a flexible linker, whose length determines the quaternary structure. Thus, they carry the complete antigen binding site in a single polypeptide chain of only about 30 kDa. In tumor targeting, scFv have demonstrated good tumor penetration, high ratios of tumor to normal tissue concentration, and low background (1, 2) . This makes them attractive targeting components of bifunctional fusion proteins such as those needed for antibodydirected enzyme-prodrug therapy (ADEPT). In ADEPT, after binding of an antibody-enzyme construct to the cognate tumor antigen, the enzyme component converts a prodrug into a cytotoxic drug, thus generating drug activity specifically in tumor tissue (3, 4) . An eminent obstacle to the development of scFv-based approaches, however, is posed by the expression of a heterogeneous protein consisting of mammalian antibody sequences and e.g. a microbial enzyme in a single expression system.
Several ADEPT systems have shown promising in vivo efficacy in a number of tumor models (5) and xenograft systems in nude mice (3, (6) (7) (8) , demonstrating in principle that ADEPT can selectively target tumor tissue and deliver chemotherapeutic drugs with high intratumoral concentrations. Senter's group first used bacterial cytosine deaminase for ADEPT to catalyze the deamination of 5-fluorocytosine (5-FC), which is non-toxic in mammals, into 5-fluorouracil (5-FU) (9) . Clinical studies on ADEPT have proven the rationale for its application in humans (10) .
The glycoprotein A33 (gpA33) is a promising target for antibody-based therapy of metastatic colorectal carcinoma. It is a transmembrane protein (11) (14) . The expression of the antigen in normal tissue is very limited; almost the only normal tissue expressing the gpA33 antigen is colonic mucosa (14) . After binding to tumor cells, the humanized anti-gpA33 antibody huA33 shows excellent retention in tumor tissue. In clinical studies with radiolabeled murine A33, the radioactive label was still traceable in tumor tissue up to 6 weeks after injection of the antibody, while it cleared from normal tissue within 1 week (15) . The same fast clearance from normal colon has been found for huA33, with a clearance rate that corresponds to the turnover time of normal colonocytes (16) .
In vitro studies of the murine mAb A33 have shown that after binding to its cognate cellular antigen, the antibody is internalized through cytoplasmic vesicles, transported to perinuclear regions, and subsequently resurfaces intact in a repetitious cycle (17) . Internalization of iodinated antibodies usually results in rapid deiodination and release of the radioiodine from the cell. However, this was not seen with 125 Ilabeled mAb A33, where prolonged retention of radioactivity in tumor sites was observed in a clinical study (15) , proving stability of the iodinated antibody under physiological conditions.
While these findings make A33 antibodies attractive targeting agents, yet no in vivo data exist on scFv-based gpA33-binding fusion proteins. A33scFv::CDy is a recombinant fusion protein comprising A33scFv, a phage-displayderived anti-gpA33 scFv (18) , and cytosine deaminase from S. cerevisiae, which efficiently converts non-toxic 5-FC into the cytotoxic drug 5-FU. Here we report on the biodistribution of 131 I-labeled A33scFv::CDy and preliminary therapeutic results with this ADEPT concept in mice.
Materials and methods
Fusion protein construct. The recombinant A33scFv::CDy fusion construct was overexpressed and secreted into culture supernatant by Pichia pastoris and purified by affinity chromatography on protein L as previously described (19) .
Cell lines. The human colon carcinoma cell lines HT29 (gpA33 negative) and LIM1215 (gpA33-positive, provided by the Ludwig Institute of Cancer Research, New York, NY) were cultivated in Dulbecco's modified Eagle's medium with Glutamax™ (PAA Laboratories GmbH, Pasching, Germany) supplemented with 10% fetal calf serum (BioChrom KG, Berlin, Germany) at 37˚C, 5% CO 2 and 95% humidity and harvested using 0.1% trypsin and 0.02% ethylenediaminetetraacetic acid (Gibco, Grand Island, NY) or, when subsequent immunostaining was required, a cell scraper (Greiner, Munich, Germany).
Radiolabeling of A33scFv::CDy. Iodination of A33scFv::CDy was performed by the chloramine-T method (20) . In brief, 400 kBq iodine-131 (GE Healthcare, Freiburg, Germany) in a volume of 40 μl was added to 280 μg A33scFv::CDy in the presence of 100 μl chloramine-T (2.0 mg/ml) to a final volume of 640 μl for 1 min. The reaction was quenched with 100 μl saturated solution of methionine (50 mg/ml). Labeled antibody was separated from free iodine using a NAP 5 column (GE Healthcare, Freiburg, Germany). Specific activity of [ 131 I]A33scFv::CDy was ~400 kBq/mg. To assess whether the binding capacity of the antibody was impaired by iodination, 2x10 6 LIM1215 or HT29 cells were incubated with 10 μg of [ 131 I]A33scFv::CDy in iodination ratios of 100, 200, or 400 kBq/mg for 1.5 h at 37˚C and subsequently washed three times with serum-free medium by centrifugation at 130 x g at room temperature. Antibody binding to cells was quantified in an automated gamma counter.
In vivo experiments. Four-to six-week-old athymic female (nu/nu) mice (body weight, 20-25 g, Charles River, Sulzfeld, Germany) were housed in groups of three to five animals in an enriched environment under standard conditions of temperature (21-24˚C), humidity (40-60%) and 12-h-lightdark-cycles. Food and water were freely available. All experiments were carried out in compliance with German law under license number G 0303/01 of the Berlin administration for health protection and social matters (Landesamt für Gesundheitsschutz und Soziales, Berlin) and adhering to the United Kingdom Coordinating Committee on Cancer Research 'Guidelines for the Welfare of Animals in Experimental Neoplasia'. After arrival at the facility, the mice were allowed to acclimatize for one week before the experiments were started.
For tumor experiments, mice were injected with 1x10 6 LIM1215 or HT29 cells subcutaneously into the right flank. After 10-14 days, mice bearing tumors of ~15-60 mg (1.3-2.5 mm diameter) were selected for continuation of the experiment.
To determine pharmacokinetics and biodistribution of the recombinant fusion construct, xenograft-bearing mice received 20 kBq of 131 I-labeled A33scFv::CDy by intravenous injection into the tail vein, and groups of four animals each were sacrificed at predefined time-points between 6 and 96 h post injection. Tumor, blood, heart, lung, liver, and kidney samples were taken and their activity determined by gamma counting for 90 sec per sample in duplicates. Relative specific activity was calculated as decay-corrected percentage of injected dose per gram of tissue (% ID/g) by reference to standards.
To assess the therapeutic efficacy of the proposed ADEPT concept of eight xenograft-bearing mice, four were intravenously injected 50 μg of A33scFv::CDy fusion protein in three fractions of a total of 100 μl phosphate buffered saline, while the remainder received saline solution as control. After 47 h, all mice received fractioned injections of a total of 15 mg of 5-FC in 200 μl saline solution with 5% (v/v) DMSO prodrug. All animals were observed for another 12 days for tumor growth and adverse effects. , 130 x g ), counted in all blocked tubes, and the mean was used as cell number for all wells. The amount of radioactivity bound to cells was determined in a gamma counter by comparison to a standard. Results were analyzed by nonlinear regression using Sigma Plot 9.0 to obtain the KD and Bmax values.
Results

Binding properties of [
131 I]A33scFv::CDy in vitro. A33scFv:: CDy was successfully radiolabeled with 131 I using the chloramine-T method. Binding activity and specificity were demonstrated by incubating either gpA33-positive LIM1215 cells or HT29 control cells with the radiolabeled fusion protein and determining radioactivity after bound-free separation. Comparing binding after radioiodination with 100-400 kBq/mg, specific binding was demonstrated up to the highest labeling dose, which was used for subsequent experiments (Fig. 1) .
Binding affinity of [ 131 I]A33scFv::CDy was determined by a saturation assay, shown in Fig. 2 , where the equilibrium dissociation constant (KD) and the binding capacity (Bmax) were determined and used as a measure of affinity. The KD value was calculated to 15.8 nM and the Bmax value was found to be 5.02 nM/2x10 6 cells. over time after injection is shown in Fig. 4 . The mean uptake of [
131 I]A33scFv::CDy by antigen-expressing LIM1215 cells reached its maximum with 87.25±8.0% ID/g at 47 h after injection and decreased in two phases thereafter, with a steep slope until 67 h after injection. In contrast, the maximal uptake in the control colon xenograft HT29 was 8.74±2.2% ID/g at 47 h (Fig. 3) . The tumor-to-blood ratio of the relative specific activity for LIM1215 tumors increased from 1.7:1 at 6 h to 8.1:1 at 67 h after injection (Fig. 4) .
The tissue distribution of [ 131 I]A33scFv::CDy in xenografted mice is shown in Fig. 5 . From 47 h post injection on, the tumor contained most of the injected activity at all time-points. During the first three measurements, however, the highest uptake was found in the kidneys, probably due to dissociation of iodine from the protein. Together with the levels in blood and all other organs, this non-specific uptake due to blood-pool activity peaked at 29 h and was well discernable from the maximum tumor uptake at 47 h.
ADEPT in vivo.
To test the feasibility of this ADEPT approach in vivo, xenograft-bearing mice were first injected the A33scFv::CDy construct and, 47 h later, the 5-FC prodrug. Tumor growth was monitored daily, and the measurements of days 0 and 12 are summarized in Fig. 6 . The overall effect is small and no mice were cured of the tumor. However, in the treated group all tumors but one shrank, and this one grew only minimally, whereas the tumors in all untreated mice grew. The differences between both groups were significant on day 12 with a p=0.0096 in the two-sided t-test, whereas a pre-existing population difference between the two groups was unlikely with a p=0.8121. Comparing day 0 to day 12 within each group, both the tumor decrease in the treated group (p=0.0376) and the growth in the control group (p=0.0182) were significant. In summary, these results make a genuine therapeutic effect highly more likely than a random effect.
Discussion
The gpA33 antigen is a promising target for radioimmunotherapy (RIT) and ADEPT of metastasized colorectal carcinoma. It is homogeneously expressed in >95% of all colorectal carcinomas with retained expression in metastases. The antigen is absent in most normal tissue apart from colonic and small intestinal mucosa and the excretory ducts of salivary glands (14) . Despite its expression in normal colonic mucosa, a clinical study with 125 I-labeled murine mAb A33 showed no severe bowel toxicity even at the highest dose (3 GBq/m 2 ) administered (15) , indicating that its expression in normal intestinal tissue does not pose a general obstacle to therapeutic application.
ADEPT has the potential to enhance the efficacy of chemotherapeutic drugs by reducing dose-limiting toxicity. First among the prerequisites to realize this potential is the selective delivery of enzyme to tumor tissue. To overcome the limitations of chemical conjugation such as larger size and heterogeneity of the product (21), we have developed the recombinant A33scFv::CDy fusion protein for use in a combination of RIT and ADEPT (19) . The bifunctional fusion protein was produced in Pichia pastoris, which allows for large-scale and high-yield expression of correctly folded and stable, glycosylated (22) protein and its secretion into culture supernatants. Although several antibody-enzyme/ prodrug systems have been developed by other groups (5), to our knowledge, A33scFv::CDy and its predecessor, A33scFv::CD, carrying the bacterial isoenzyme (23) , are the first single chain antibody fusion proteins against the gpA33-antigen.
In our pharmacokinetic and biodistribution studies in mice with an established xenograft model of gpA33-positive LIM1215 cells, A33scFv::CDy was able to penetrate into tumor tissue and localize in the gpA33-positive, viable regions despite its high molecular weight and the diffusion barriers observed for solid tumors (24, 25) . The specificity of this localization was demonstrated by lack of radioactivity in gpA33-negative HT29 control tumors. Clearance from blood and solid organs preceded the peak concentration in tumor, leaving a useful therapeutic window. However, decreasing tumor doses are observed even while the blood levels are still at their highest. This may be explained either by actual dissociation of radiolabeled fusion protein from the tumor or by the dissociation of iodine from the fusion protein, e.g. due to de-iodinase activity. The latter might be prevented and the correct answer to this question revealed by using a different radionuclide in future studies. Still, our current results indicate that the fusion construct is specifically bound and retained in tumor tissue, because after blood clearance, a lower, but constant plateau of the tumor-to-blood ratio is reached. This can hardly be explained by passive diffusion kinetics, but rather by a stable fraction within tumor tissue which is not accessible to serum enzymes.
To achieve faster clearance and higher tumor to plasma ratios, three-phase systems using clearance antibodies have successfully been employed (26) (27) (28) (29) (30) , an approach that might further improve the system proposed here.
Testing the ADEPT system in vivo, we found a small but highly significant therapeutic effect in mice bearing LIM1215 xenografts. While no mice were cured, all treated mice had minor responses or stable disease, while in all untreated mice the tumors grew. Both the differences over time within each group and the difference between both groups after treatment were statistically significant. If this indicates a therapeutic effect of the ADEPT system, why was it not stronger? The answer may be an inherent problem of murine xenograft models for ADEPT, as targeting and drug exposure of the tumor happen at two different time-points. Hence, the tumor may outgrow its enzyme-labeled proportion in this interval, giving a false-pessimistic result. To avoid this effect, we chose a relatively slow-growing tumor model. This, in turn, may have the effect that too small a number of cells is sensitive to chemotherapy at any given time. In either case, these findings stress the importance of dose, timing, and repeat applications, which require more detailed investigation in the future.
In addition to 131 I (31), the murine A33 antibody has previously been conjugated with 90Y in a preclinical report (32) . The different ranges of beta radiation emitted from 90Y and 131 I [5.3 and 0.83 mm, respectively (33)] may be exploited for different situations in tumor disease, either alone or in combination (34) .
In conclusion, we demonstrated in this study that A33scFv::CDy has favorable pharmacokinetic characteristics for the use in RIT and ADEPT and that its application in ADEPT is feasible and leads to therapeutic effects in a murine model. These results open a perspective towards antibody-targeted combined radio-chemotherapy, which might be dubbed Radio-ADEPT. Future studies of this system will reveal the potential therapeutic effect of A33scFv::CDy in ADEPT and RIT alone, respectively, and in this combination concept, including selection of the optimal radionuclide and optimization of dose and time schedules.
